S Conclus

-5-

48. A method of preventing or treating a disease caused by or contributed by the activity or level of Mcm3 expression, comprising administering to the subject an effective amount of a pharmaceutical composition comprising an antibody according to Claim 25 together with a pharmaceutically acceptable carrier.

REMARKS

This application is the United States national application arising from International Application No. PCT/EP00/02910.

The original claims of the International Application have been canceled and substituted with new claims of the same scope but in a better format for United States applications.

For the convenience of the Examiner, a complete set of the new claims is attached to this Amendment under the heading "Claims Pending, as Amended Herein".

In the International Preliminary Examination Report issued in the International Application on May 28, 2001, all claims having the scope of those now present in the application were indicated to be novel, nonobvious and useful.

Applicant's Attorney hereby authorizes the Patent Office to charge any additional fees to Deposit Account No. 08-0380. A copy of this letter is enclosed for accounting purposes.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

David E. Brook

Registration No. 22,591

Telephone: (781) 861-6240 Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: 9/27/01